Rapid Micro Biosystems 미래 성장

Future 기준 확인 1/6

Rapid Micro Biosystems은 연간 수입과 매출이 각각 9.3%와 18% 증가할 것으로 예상되고 EPS는 연간 9.7%만큼 증가할 것으로 예상됩니다.

주요 정보

9.3%

수익 성장률

9.7%

EPS 성장률

Life Sciences 수익 성장	16.0%
매출 성장률	18.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	03 Mar 2025

최근 미래 성장 업데이트

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05

Recent updates

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Apr 21

MilliporeSigma And Lonza Collaborations Will Expand Market Reach

Apr 11 The global agreement with MilliporeSigma is set to expand Growth Direct's market reach and potentially enhance supply chain efficiency, boosting future revenues.

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 05

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Looks Just Right With A 70% Price Jump

Mar 02

Investors Still Aren't Entirely Convinced By Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Revenues Despite 27% Price Jump

Jan 16

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Nov 02

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Oct 29

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Aug 03

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Jun 30

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Oct 10

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

May 09

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Mar 08

We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

Feb 07

수익 및 매출 성장 예측

NasdaqCM:RPID - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	40	-39	-28	-27	2
12/31/2025	33	-43	-32	-31	2
12/31/2024	28	-47	-46	-44	N/A
9/30/2024	26	-48	-45	-44	N/A
6/30/2024	25	-50	-47	-45	N/A
3/31/2024	23	-52	-46	-44	N/A
12/31/2023	23	-52	-47	-45	N/A
9/30/2023	21	-58	-49	-47	N/A
6/30/2023	19	-61	-56	-53	N/A
3/31/2023	18	-60	-64	-58	N/A
12/31/2022	17	-61	-65	-59	N/A
9/30/2022	18	-59	-68	-60	N/A
6/30/2022	20	-68	-71	-64	N/A
3/31/2022	22	-69	-66	-61	N/A
12/31/2021	23	-78	-58	-55	N/A
9/30/2021	23	-77	-49	-47	N/A
6/30/2021	22	-63	-38	-37	N/A
3/31/2021	18	-60	-35	-34	N/A
12/31/2020	16	-45	-32	-31	N/A
12/31/2019	17	-27	-23	-21	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RPID 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RPID 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RPID 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RPID 의 수익(연간 18% ) US 시장( 8.3% 보다 빠르게 성장할 것으로 예상됩니다. 8.3% 연간).

고성장 수익: RPID 의 수익(연간 18% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RPID 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/04/30 17:42
장 마감 주가	2025/04/30 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Rapid Micro Biosystems, Inc. 6 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Tycho Peterson	J.P. Morgan
Paul Knight	KeyBanc Capital Markets Inc.
Tejas Savant	Morgan Stanley

Rapid Micro Biosystems 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported And Analysts Have Been Lifting Their Price Targets

Rapid Micro Biosystems, Inc. Provides Earnings Guidance for the Full Year 2025

Rapid Micro Biosystems, Inc. Re-Affirms Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Recent updates

Rapid Micro Biosystems, Inc. to Report Q1, 2025 Results on May 09, 2025

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

MilliporeSigma And Lonza Collaborations Will Expand Market Reach

Rapid Micro Biosystems, Inc., Annual General Meeting, May 22, 2025

New minor risk - Market cap size

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported And Analysts Have Been Lifting Their Price Targets

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Looks Just Right With A 70% Price Jump

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rapid Micro Biosystems, Inc. Provides Earnings Guidance for the Full Year 2025

Rapid Micro Biosystems, Inc. to Report Q4, 2024 Results on Feb 28, 2025

New minor risk - Share price stability

Investors Still Aren't Entirely Convinced By Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Revenues Despite 27% Price Jump

Insufficient new directors

New major risk - Revenue and earnings growth

Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story

Rapid Micro Biosystems, Inc. Re-Affirms Revenue Guidance for the Full Year 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?

Rapid Micro Biosystems, Inc. to Report Q3, 2024 Results on Nov 01, 2024

Independent Director recently bought US$50k worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb

Rapid Micro Biosystems, Inc. to Report Q2, 2024 Results on Aug 02, 2024

We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. to Report Q1, 2024 Results on May 03, 2024

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Rapid Micro Biosystems, Inc. Provides Revenue Guidance for the Full Year 2024

Rapid Micro Biosystems, Inc. to Report Fiscal Year 2023 Results on Mar 01, 2024

Rapid Micro Biosystems, Inc. Receives A Non-Compliance Notification Letter from the Nasdaq

Rapid Micro Biosystems Announces the Upcoming Availability of Rapid Sterility Application for the Growth Direct® System

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Fiscal Year 2023

Rapid Micro Biosystems, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Rapid Micro Biosystems Receives a Notification Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Rapid Micro Biosystems, Inc. Appoints of Kirk Malloy as Chair of Its Board of Directors

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance for the Full Year of 2023

Consensus revenue estimates fall by 11%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2022 Results on Mar 03, 2023

Rapid Micro Biosystems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022

Rapid Micro Biosystems, Inc. Announces Publication of Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$9.00

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.71 loss in 3Q 2021)

Rapid Micro Biosystems, Inc. Reaffirms Full Year 2022 Revenue Outlook

Rapid Micro Biosystems, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Rapid Micro Biosystems, Inc. Announces RMBnucleus Mold Alarm for the Growth Direct System

Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing

Kennedy Lewis Capital Partners Master Fund II LP and Kennedy Lewis Capital Partners Master Fund III LP managed by Kennedy Lewis Investment Management LLC cancelled the acquisition of remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID).

Rapid Micro Biosystems, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rapid Micro Biosystems, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Kennedy Lewis Investment Management LLC delivered a Non-Binding Proposal to acquire remaining 85.67% stake in Rapid Micro Biosystems, Inc. (NasdaqGS:RPID) for approximately $160 million.

Rapid Micro Biosystems, Inc.(NasdaqGS:RPID) dropped from Russell 2500 Value Index

Rapid Micro Biosystems, Inc. Reaffirms Earnings Guidance For Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth

Rapid Micro Biosystems, Inc., Annual General Meeting, May 23, 2022

Alexander Schmitz Not to Stand for Reelection as Member of the Board of Directors of Rapid Micro Biosystems, Inc

Insider recently bought US$70k worth of stock

Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67

Rapid Micro Biosystems, Inc. Reaffirms Revenue Guidance Full Year 2022

Full year 2021 earnings: Revenues in line with analyst expectations

Rapid Micro Biosystems, Inc. to Report Q4, 2021 Results on Mar 04, 2022